RxDoctor Payments Data

Soraya Samii, MD

Clinical Cardiac Electrophysiology · Hershey, PANPI 1386619773

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (44.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Boston Scientific at 49.6% of the total. Reporting peaked in 2019 at $30,461 and has fallen 91.8% since, to $2,506 in 2025.

$56,833in general payments, 2019–2025

Across 167 payments — averaging $340.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$28K
  • Medtronic$14K
  • Acutus Medical, Inc.$9K
  • Abbott$4K
  • Biotronik Inc.$1K
  • Impulse Dynamics (USA) Inc.$84
  • plus $116 from 3 others
$140,583in research payments, 2019–2025

Across 450 payments — averaging $312.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotronik Inc.$79K
  • Boston Scientific$48K
  • Abbott$13K

What the payments were for

  • Consulting fees$18,70033%
  • Speaking & faculty fees$6,10011%
  • Travel & lodging$25,03344%
  • Food & beverage$6,94112%
  • Education$600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,833 in reported general payments places this provider in the 75th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

See all clinical cardiac electrophysiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$103,221
Medicare patients
996
Services billed
2,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$67,685
XareltoRivaroxaban26$25,078
MultaqDronedarone Hcl11$14,315
JardianceEmpagliflozin19$11,667
Metoprolol Succinate77$1,625
Amiodarone Hcl32$571
Diltiazem 24hr Er (Cd)Diltiazem Hcl18$407
Flecainide Acetate11$204
Losartan Potassium24$168
Atenolol11$136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$67,68575 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

Other clinical cardiac electrophysiology in Hershey

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →